Budesonide Attains Its Wide Clinical Profile by Alternative Kinetics

Area of Science:

• Pulmonology
• Pharmacology
• Clinical Medicine

Background:

• Inhaled corticosteroids (ICSs) revolutionized mild-to-moderate asthma management by prioritizing inflammation reduction over bronchodilation.
• Early ICS development, like beclomethasone dipropionate (BDP), highlighted the importance of low water solubility for prolonged airway action.
• This established a paradigm linking ICS efficacy and safety to specific physicochemical properties.

Purpose of the Study:

• To explore the development and therapeutic impact of budesonide (BUD) as a key inhaled corticosteroid.
• To elucidate the distinct pharmacokinetic and pharmacodynamic mechanisms underlying BUD's efficacy and safety profile.
• To demonstrate BUD's role in advancing asthma treatment guidelines and therapeutic strategies.

Main Methods:

• Review of clinical trials and pharmacological studies on budesonide (BUD) and other inhaled corticosteroids (ICSs).
• Comparative analysis of physicochemical properties (e.g., lipophilicity, water solubility) influencing drug absorption and action.
• Examination of BUD's unique intracellular esterification and systemic absorption profiles.

Main Results:

• Budesonide (BUD), despite higher water solubility than BDP, achieves prolonged airway efficacy via intracellular esterification and rapid systemic uptake with short plasma peaks.
• Clinical trials established BUD as a first-line treatment for all asthma severities, supporting early intervention strategies.
• The development of budesonide/formoterol (BUD/FORM) combinations led to effective maintenance and reliever therapy (MART) and as-needed anti-inflammatory reliever (AIR) approaches.

Conclusions:

• Budesonide (BUD) represents a significant advancement in inhaled corticosteroid therapy, offering a favorable efficacy/safety balance through multifaceted mechanisms.
• BUD's clinical success has reshaped asthma management, promoting early intervention and versatile treatment regimens.
• The evolution of BUD-based therapies, including combination inhalers, continues to influence international asthma guidelines and improve patient care.